Monoamine Oxidase

hMAO-B-IN-4 (compound B10) is a selective, reversible, and BBB-penetrable inhibitor of human monoamine oxidase-B (hMAO-B), with IC50 and Ki values of 0.067 and 0.03 μM, respectively. The IC50 value for hMAO-A inhibition by hMAO-B-IN-4 is 33.82 μM. hMAO-B-IN-4 can be used in research on Alzheimer's disease and Parkinson's disease.

Ladostigil (TV-3326) hydrochloride is an orally effective dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50 values of 37.1 and 31.8 μM for inhibiting MAO-B and AChE, respectively. Ladostigil hydrochloride has neuroprotective, antioxidant, and anti-inflammatory effects, making it useful in the research of depression and Alzheimer's disease.

MAO-B-IN-8 is an effective reversible MAO-B inhibitor and a small glial cell generation inhibitor of neuroinflammatory mediators. MAO-B-IN-8 can be used for research on neurodegenerative diseases.

Nrf2-ARE/hMAO-B/QR2 modulator 1 is a multi-targeted ligand based on resveratrol, with IC50 values of 8.05 μM, 9.83 μM and 0.57 μM for hMAO-B, NRF2 and QR2 respectively. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotective effects and can reduce ROS production in mouse hippocampal slices treated with okadaic acid.

Pheniprazine hydrochloride is an effective long-acting monoamine oxidase inhibitor. It has the potential to be used in research for treating depression.

CAD031 is a derivative of the Alzheimer's disease (AD) targeting agent J147 with neuroprotective and memory-enhancing properties.

(R)-Safinamide, the enantiomer of safinamide , can inhibit MAO-B with an IC50 value of 0.45 μM.

AChE/BChE/MAO-B-IN-1 (Compound 10) is a reversible and non-time-dependent AChE, BChE and MAO-B inhibitor with IC50 values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively.

MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively.

MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC50 value of 5.08 μM.

MAO-B-IN-30 (compound IS7) is a potent, selective and cross the blood-brain barrier MAO-B inhibitor with IC50 values of 19.176, 0.082 µM for MAO-A and MAO-B, respectively.

hMAO-B-IN-5(B15) is a potent, selective and reversible inhibitor of human monoamine oxidase hMAO-B with IC50 of 0.12 μM.

Tisolagiline (KDS2010) is a reversible MAO-B inhibitor used in Parkinson's disease research.

Lysyl droxylase 2-IN-1 (compound 12) is a selective lysyl droxylase 2 (LH2) Inhibitor with an IC50 of ~300 nM.

HIF-1α-IN-5 is a HIF-1α inhibitor with an IC50 value of 24 nM (in HEK293T cell).

MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC50s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively.

LSD1/HDAC6-IN-2 (JBI-802) is an orally active LSD1/HDAC6/MAO-A inhibitor, with IC50 values of 5 nM, 11 nM, and 5 nM, respectively.

Ethaverine drochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel.

Pirlindole hydrochloride is an orally active, selective and reversible MAO-A inhibitor with an IC 50 value of 250 nM.

2-Phenylcyclopropanamine (Compound 3) is an irreversible inhibitor of MAO-A/B and LSD1.

(R)-Liquiritigenin ((R)-4',7-Dihydroxyflavanone) is a MAO inhibitor that acts as an inhibitor of recombinant human MAO-A ( IC 50 9.97 μM) and recombinant human MAO-B ( IC 50 3.91 μM).

MAO-B-IN-55 (Compound 5c) is a reversible competitive MAO-B inhibitor with an IC 50 of 2.9 nM, and it exhibits approximately 2750-fold higher selectivity for MAO-B over MAO-A.

4-Chlorochalcone (Compound 3) is a monoamine oxidase inhibitor (hMAO-B: IC 50 = 0.082 μM, hMAO-A: IC 50 = 9.95 μM).

MODAG-005 is a blood-brain barrier-permeable PET probe precursor for α-synuclein ( α‑Syn ) aggregates, with a K i value of 0.4 nM and a K d value of 0.2 nM.